UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006465
Receipt number R000007672
Scientific Title Comparison and evaluation of different effects of three alpha-Glucosidase inhibitors on lowering blood sugar and body weight in Japanese obese patients with type 2 diabetes
Date of disclosure of the study information 2011/10/04
Last modified on 2018/06/27 13:58:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparison and evaluation of different effects of three alpha-Glucosidase inhibitors on lowering blood sugar and body weight in Japanese obese patients with type 2 diabetes

Acronym

Nippon Medical School Group:Clinical Usefulness Research of alpha-glucosidase inhibitor Effect on Type 2 Diabetes Mellitus with Obesity (N-CURE Study)

Scientific Title

Comparison and evaluation of different effects of three alpha-Glucosidase inhibitors on lowering blood sugar and body weight in Japanese obese patients with type 2 diabetes

Scientific Title:Acronym

Nippon Medical School Group:Clinical Usefulness Research of alpha-glucosidase inhibitor Effect on Type 2 Diabetes Mellitus with Obesity (N-CURE Study)

Region

Japan


Condition

Condition

Type 2 Diabetes Mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

In this study, we compare Miglitol, Acarbose, and Voglibose, with a control group comprised of patients who received no alpha-GI therapy, on their effects on glycemic and weight control and other clinical benefits in Japanese obese patients with type 2 diabetes.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

HbA1c,1.5-AG,Body Weight,BMI

Key secondary outcomes

FPG,Serum Insulin,HOMA-IR,Adiponectin,Leptin,
Questionnaires(digestive symptoms,appetite,drug compliance)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment

Central registration


Intervention

No. of arms

4

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Miglitol 150mg/day 12weeks

Interventions/Control_2

Voglibose 0.9mg/day 12weeks

Interventions/Control_3

Acarbose 300mg/day 12weeks

Interventions/Control_4

Non-alpha-GI-treated 12weeks

Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Japanese patients of both sexes, age 40 or older who were under the care of one of the study centers and who were obese patients with type 2 diabetes with an HbA1c of 6.4% to 8.4% (NGSP) and a body mass index (BMI) of 25 kg/m2 or above.

Key exclusion criteria

Patients on insulin therapy and patients with a serious hepatic, renal, or cardiac disease

Target sample size

80


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shinichi Oikawa

Organization

Nippon Medical School

Division name

Division of Endocrinology and Metabolism, Department of Medicine

Zip code


Address

1-1-5, Sendagi,Bunkyo-ku,Tokyo

TEL

03-3822-2131

Email

shinichi@nms.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shinichi Oikawa

Organization

Nippon Medical School

Division name

Division of Endocrinology and Metabolism, Department of Medicine

Zip code


Address

1-1-5, Sendagi,Bunkyo-ku,Tokyo

TEL

03-3822-2131

Homepage URL


Email

shinichi@nms.ac.jp


Sponsor or person

Institute

Nippon Medical School

Institute

Department

Personal name



Funding Source

Organization

SANWA KAGAKU KENKYUSHO CO.,LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

日本医科大学附属病院(東京都)、国民健康保険八丈町立八丈病院(東京都)、自治医科大学附属さいたま医療センター(埼玉県)、乙成内科医院(福岡県)、柏市立柏病院(千葉県)


Other administrative information

Date of disclosure of the study information

2011 Year 10 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 09 Month 11 Day

Date of IRB


Anticipated trial start date

2007 Year 10 Month 01 Day

Last follow-up date

2011 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 10 Month 04 Day

Last modified on

2018 Year 06 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007672


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name